Literature DB >> 26172402

Acquired isodisomy on chromosome 13 at diagnosis results in impaired overall survival in patients with FLT3-ITD mutant acute myeloid leukaemia.

J C T Loke1, S Akiki2, J Borrow2, J Ewing3, S W Bokhari4, D Chandra5, J Arrazi1, P Hazlewood1, K Arthur6, J Walsh7, Y Membwange8, F A Wandroo8, A Watts9, A Borg10, K Brock11, P Ferguson1, C Craddock1, M Griffiths2, M Raghavan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26172402     DOI： 10.1038/leu.2015.148

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Acquired isodisomy for chromosome 13 is common in AML, and associated with FLT3-itd mutations.

Authors:  M Griffiths; J Mason; M Rindl; S Akiki; D McMullan; V Stinton; H Powell; A Curtis; N Bown; C Craddock
Journal:  Leukemia       Date:  2005-12       Impact factor: 11.528

2.  Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation.

Authors:  Richard F Schlenk; Sabine Kayser; Lars Bullinger; Guido Kobbe; Jochen Casper; Mark Ringhoffer; Gerhard Held; Peter Brossart; Michael Lübbert; Helmut R Salih; Thomas Kindler; Heinz A Horst; Gerald Wulf; David Nachbaur; Katharina Götze; Alexander Lamparter; Peter Paschka; Verena I Gaidzik; Veronica Teleanu; Daniela Späth; Axel Benner; Jürgen Krauter; Arnold Ganser; Hartmut Döhner; Konstanze Döhner
Journal:  Blood       Date:  2014-09-30       Impact factor: 22.113

3.  The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.

Authors:  P D Kottaridis; R E Gale; M E Frew; G Harrison; S E Langabeer; A A Belton; H Walker; K Wheatley; D T Bowen; A K Burnett; A H Goldstone; D C Linch
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

4.  Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.

Authors:  S P Whitman; K J Archer; L Feng; C Baldus; B Becknell; B D Carlson; A J Carroll; K Mrózek; J W Vardiman; S L George; J E Kolitz; R A Larson; C D Bloomfield; M A Caligiuri
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

5.  Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors.

Authors:  Panagiotis D Kottaridis; Rosemary E Gale; Stephen E Langabeer; Marion E Frew; David T Bowen; David C Linch
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

6.  FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.

Authors:  Keith W Pratz; Takashi Sato; Kathleen M Murphy; Adam Stine; Trivikram Rajkhowa; Mark Levis
Journal:  Blood       Date:  2009-12-10       Impact factor: 22.113

7.  Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy.

Authors:  Marta Pratcorona; Salut Brunet; Josep Nomdedéu; Josep Maria Ribera; Mar Tormo; Rafael Duarte; Lourdes Escoda; Ramon Guàrdia; M Paz Queipo de Llano; Olga Salamero; Joan Bargay; Carmen Pedro; Josep Maria Martí; Montserrat Torrebadell; Marina Díaz-Beyá; Mireia Camós; Dolors Colomer; Montserrat Hoyos; Jorge Sierra; Jordi Esteve
Journal:  Blood       Date:  2013-02-01       Impact factor: 22.113

8.  Most acute myeloid leukaemia patients with intermediate mutant FLT3/ITD levels do not have detectable bi-allelic disease, indicating that heterozygous disease alone is associated with an adverse outcome.

Authors:  Claire Green; David C Linch; Rosemary E Gale
Journal:  Br J Haematol       Date:  2008-06-03       Impact factor: 6.998

9.  Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia.

Authors:  Manoj Raghavan; Lan-Lan Smith; Debra M Lillington; Tracy Chaplin; Ioannis Kakkas; Gael Molloy; Claude Chelala; Jean-Baptiste Cazier; James D Cavenagh; Jude Fitzgibbon; T Andrew Lister; Bryan D Young
Journal:  Blood       Date:  2008-05-19       Impact factor: 22.113

10.  FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia.

Authors:  Benjamin H Lee; Zuzana Tothova; Ross L Levine; Kristina Anderson; Natalija Buza-Vidas; Dana E Cullen; Elizabeth P McDowell; Jennifer Adelsperger; Stefan Fröhling; Brian J P Huntly; Miloslav Beran; Sten Eirik Jacobsen; D Gary Gilliland
Journal:  Cancer Cell       Date:  2007-10       Impact factor: 31.743
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.